rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The protein C (PC), protein S, antithrombin activities, homocysteine levels, and factor V Leiden (FVL) G1691A and prothrombin G20210A mutations were evaluated in 191 patients with VTE and 191 controls.
|
17895505 |
2008 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The C677T mutation of the methylenetetrahydrofolate reductase gene, which may lead to hyperhomocysteinemia, is also considered a risk factor for VTE in some studies.
|
17401546 |
2007 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism.
|
15886665 |
2005 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Insofar as the inherited prothrombotic single nucleotide polymorphisms (SNPs) factor V G1691A (FV-Leiden), prothrombin (PRT) G20210A, and methylenetetrahydrofolate reductase (MTHFR), C677T are inherited risk factors of venous thromboembolism (VTE), the aim of this study was to determine the prevalence of single and combined SNPs in 198 patients with documented deep venous thrombosis (DVT), and 697 control subjects, and to estimate the associated risks.
|
16082606 |
2005 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism.
|
16261289 |
2005 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Insofar as the inherited prothrombotic single nucleotide polymorphisms (SNPs) factor V G1691A (FV-Leiden), prothrombin (PRT) G20210A, and methylenetetrahydrofolate reductase (MTHFR), C677T are inherited risk factors of venous thromboembolism (VTE), the aim of this study was to determine the prevalence of single and combined SNPs in 198 patients with documented deep venous thrombosis (DVT), and 697 control subjects, and to estimate the associated risks.
|
16082606 |
2005 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are considered risk factors for venous thromboembolism.
|
15886665 |
2005 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single point mutations in the genes coding for factor V [G1691A; Leiden], prothrombin [PRT; G20210A], and methylenetetrahydrofolate reductase [MTHFR, C677T] were shown to be major inherited predisposing factors for venous thromboembolism.
|
15353918 |
2004 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single point mutations in the genes coding for factor V [G1691A; Leiden], prothrombin [PRT; G20210A], and methylenetetrahydrofolate reductase [MTHFR, C677T] were shown to be major inherited predisposing factors for venous thromboembolism.
|
15353918 |
2004 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No associations between VTE and MTHFR polymorphisms (C677T, A1298C) were found.
|
12570104 |
2003 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Factor V Leiden, prothrombin 20210G --> A, methylenetetrahydrofolate reductase 677C --> T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism.
|
14597244 |
2003 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy.
|
10759281 |
2000 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequencies of Factor V G1691A (FVL), prothrombin (PT) G20210A, 5'10'methylenetetrahydrofolate reductase (MTHFR) C677T, and methionine synthase (MS) A2756G (four mutations associated with an increased risk of venous thromboembolism [VTE]) were determined in a sample of approximately 1500 New York State residents.
|
10963782 |
2000 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study suggests that the homozygous C677T mutation in the MTHFR gene might be a risk factor of VTE in patients with spontaneous events and without other common genetic risk factors.
|
11124649 |
2000 |
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism.
|
11011848 |
2000 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequencies of Factor V G1691A (FVL), prothrombin (PT) G20210A, 5'10'methylenetetrahydrofolate reductase (MTHFR) C677T, and methionine synthase (MS) A2756G (four mutations associated with an increased risk of venous thromboembolism [VTE]) were determined in a sample of approximately 1500 New York State residents.
|
10963782 |
2000 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7).
|
11071628 |
2000 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
|
10456622 |
1999 |
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
|
10365737 |
1999 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations.
|
31676865 |
2019 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
|
30439355 |
2019 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In non-oral contraceptive users the risk of venous thromboembolism was significantly increased in carriers of R506Q but not in those with the G20210A mutation.
|
12069454 |
2002 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The determination of the factor II: G20210A variant in index patients carrying a factor V: R506Q mutation and, if present, in family members may help to identify individuals who are at high risk for VTE.
|
11737249 |
2001 |
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Because both factor V R506Q</span> and the HR2 haplotype are very frequent, the effect of their coinheritance on the risk of venous thromboembolism might represent a clinically relevant issue, and screening for HR2 in carriers of factor V R506Q should be considered.
|
10556190 |
1999 |